On the stock market since 2015, it operates in the world of health and science. It has 3,300 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades 16% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 11% a year on average.
The company sells $1.4B a year; the problem isn’t sales — it’s costs running above that number.
There is $635.6M in the vault; even if every debt were paid off, $162.3M would remain.
A loss of $242.5M against $1.4B in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, LIVN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: LIVN has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.